Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/66679
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Título

Pharmacologic inhibitors of extracellular signal-regulated kinase (MEK/ERKs) and c-Jun NH2-terminal kinase (JNK) decrease glutathione content and sinsitize human promonocytic leukemia cells to arsenic trioxide-induced apoptosis

AutorRamos, Adrián M. CSIC; Fernández, Carlos CSIC; Esteban, Diego; Amrán, Donna CSIC; Blas, Elena de CSIC; Palacios, María A.; Aller, Patricio CSIC
Fecha de publicacióndic-2006
EditorWiley-Blackwell
CitaciónJournal of Cellular Physiology 209(3):1006-1015(2006)
ResumenTreatment with 1–4 µM As2O3 slightly induced apoptosis in U-937 human promonocitic leukemia cells. This effect was potentiated by co-treatment with MEK/ERK (PD98059, U0126) and JNK (SP600125, AS601245) inhibitors, but not with p38 (SB203580, SB220025) inhibitors. However, no potentiation was obtained using lonidamine, doxorubicin, or cisplatin instead of As2O3. Apoptosis potentiation by mitogen-activated protein kinase (MAPK) inhibitors involved both the intrinsic and extrinsic executionary pathways, as demonstrated by Bax activation and cytochrome c release from mitochondria, and by caspase-8 activation and Bid cleavage, respectively; and the activation of both pathways was prevented by Bcl-2 over-expression. Treatment with MEK/ERK and JNK inhibitors, but not with p38 inhibitors, caused intracellular glutathione (GSH) depletion, which was differentially regulated. Thus, while it was prevented by N-acetyl-L-cysteine (NAC) in the case of U0126, it behaved as a NAC-insensitive process, regulated at the level of DL-buthionine-(S,R)-sulfoximine (BSO)-sensitive enzyme activity, in the case of SP600125. The MEK/ERK inhibitor also potentiated apoptosis and decreased GSH content in As2O3-treated NB4 human acute promyelocytic leukemia (APL) cells, but none of these effects were produced by the JNK inhibitor. MEK/ERK and JNK inhibitors did not apparently affect As2O3 transport activity, as measured by intracellular arsenic accumulation. SP600126 greatly induced reactive oxygen species (ROS) accumulation, while BSO and U0126 had little or null effects. These results, which indicate that glutathione is a target of MAP kinases in myeloid leukemia cells, might be exploited to improve the antitumor properties of As2O3, and provide a rationale for the use of kinase inhibitors as therapeutic agents
Descripción10 páginas, 6 figuras -- PAGS nros. 1006-1015
Versión del editorhttp://dx.doi.org/10.1002/jcp.20806
URIhttp://hdl.handle.net/10261/66679
DOI10.1002/jcp.20806
ISSN0021-9541
E-ISSN1097-4652
Aparece en las colecciones: (CIB) Artículos




Ficheros en este ítem:
Fichero Descripción Tamaño Formato
restringido.pdf21,67 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo

CORE Recommender

SCOPUSTM   
Citations

41
checked on 23-abr-2024

WEB OF SCIENCETM
Citations

38
checked on 26-feb-2024

Page view(s)

359
checked on 24-abr-2024

Download(s)

235
checked on 24-abr-2024

Google ScholarTM

Check

Altmetric

Altmetric


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.